Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - rasburicase - powder and solvent for solution for infusion - 7.5mg

Australia - englanti - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rasburicase -

Saudi-Arabia - englanti - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sanofi aventis france, france - rasburicase - powder and solvent for solution for infusion - 7.5 mg

Saudi-Arabia - englanti - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sanofi aventis france, france - rasburicase - powder and solvent for solution for infusion - 1.5 mg

Armenia - englanti - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

f. hoffmann-la roche ltd. 4303 kaiseraugst- batch releaser - obinutuzumab - concentrate for solution for infusion - 1000mg/40ml

Israel - englanti - Ministry of Health

roche pharmaceuticals (israel) ltd - obinutuzumab - concentrate for solution for infusion - obinutuzumab 1000 mg / 40 ml - obinutuzumab - chronic lymphocytic leukaemia (cll)gazyva, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (cll).follicular lymphoma (fl )gazyva, in combination with bendamustine followed by gazyva monotherapy, is indicated for the treatment of patients with follicular lymphoma (fl) who did not respond or who progressed during or up to 6 months after treatment with a rituximab-containing regimen.gazyva in combination with chemotherapy, followed by gazyva maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.

Armenia - englanti - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

f. hoffmann-la roche ltd. 4303 kaiseraugs- secondary packager - obinutuzumab - concentrate for solution for infusion - 1000mg/40ml

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

roche products ltd - obinutuzumab - solution for infusion - 25mg/1ml

Australia - englanti - Department of Health (Therapeutic Goods Administration)

bridgewest perth pharma pty ltd - lidocaine hydrochloride monohydrate, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - lignocaine is indicated for the production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication or following resuscitation from cardiac arrest.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

bridgewest perth pharma pty ltd - lidocaine hydrochloride monohydrate, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - lignocaine is indicated for the production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication or following resuscitation from cardiac arrest.